tirzepatide ema GLP-1 shortages are not expected to resolve this year, says Director Tirzepatide | C225H348N48O68 | CID

Cancer 126 , 405415 (2010)

23431, May 1, 2026), to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facilities bulk drug substances list - finding no clinical need for large-scale outsourcing facilities to compound these medications when FDA-approved supply is commercially available

No safety information exists for breastfeeding with these medications

GLP-1 activation promotes satiation even with smaller meals, while GIP activation enhances sugar processing and insulin regulation

EMERGING BIOMARKERS TO ASSESS CARDIOVASCULAR RISK As noted above, traditional scores often fall short of accurately predicting cardiovascular risk in patients with MASLD [28-30]

4 , e525 (2013)